Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Rick Lesniewski"'
Autor:
Dimitri Semizarov, Rick Lesniewski, Guido Sauter, Stephen K. Tahir, Gang Wang, Mark G. Anderson, Charles Van Sant, Edward T. Olejniczak
Cancer is a highly heterogeneous disease in terms of the genetic profile and the response to therapeutics. An early identification of a genomic marker in drug discovery may help select patients that would respond to treatment in clinical trials. Here
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2a93be6ecf2f02b04c78232a3c5db95
https://doi.org/10.1158/1541-7786.c.6542718.v1
https://doi.org/10.1158/1541-7786.c.6542718.v1
Autor:
Dimitri Semizarov, Rick Lesniewski, Guido Sauter, Stephen K. Tahir, Gang Wang, Mark G. Anderson, Charles Van Sant, Edward T. Olejniczak
Supplementary Table S3 from Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f070759111d30eeaa00eabf58e85394
https://doi.org/10.1158/1541-7786.22520652
https://doi.org/10.1158/1541-7786.22520652
Supplementary Figure 3 from A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b45101aaba11bce68fd4b0de68eed0d8
https://doi.org/10.1158/1535-7163.22484748
https://doi.org/10.1158/1535-7163.22484748
Supplementary Figure 2D-E from A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4459773f3393f00174371718092acf8c
https://doi.org/10.1158/1535-7163.22484751.v1
https://doi.org/10.1158/1535-7163.22484751.v1
Evasion of apoptosis is a known feature of cancer cells. One mechanism of deregulating the apoptotic pathway is through overexpression of antiapoptotic BCL2 family members. ABT-263 (navitoclax) is a first-in-class BCL2 family inhibitor that restores
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7523616333f452ffe6b7aed66b71d059
https://doi.org/10.1158/1535-7163.c.6531561
https://doi.org/10.1158/1535-7163.c.6531561
Supplementary Figure 2A-C from A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::798caa87e5b9a41a8df76d2ec625fd7e
https://doi.org/10.1158/1535-7163.22484754.v1
https://doi.org/10.1158/1535-7163.22484754.v1
Supplementary Figure 1 from A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59e94a5af2bf84008270fdc190d79b84
https://doi.org/10.1158/1535-7163.22484757
https://doi.org/10.1158/1535-7163.22484757
Supplementary Figure Legends from A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afef2177199aa8e2760ed0e096453e2f
https://doi.org/10.1158/1535-7163.22484742.v1
https://doi.org/10.1158/1535-7163.22484742.v1
Supplementary Figure 4 from A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d54807b054785f7165d8aafe1e32a0d
https://doi.org/10.1158/1535-7163.22484745.v1
https://doi.org/10.1158/1535-7163.22484745.v1
Autor:
Peter Ansell, Evelyn McKeegan, Haiying Zhang, John Xue, Rick Lesniewski, Sevan Brodjian, Don J. Davidson, John E. Harlan
Publikováno v:
European Journal of Cancer. 46:966-973
The blood protein plasminogen is proteolytically cleaved to produce angiostatin and kringle 5 (K5), both of which are known angiogenesis inhibitors. A common structural element between K5, angiostatin and other endogenous angiogenesis inhibitors is t